EMA approves use of Pfizer in adolescents aged 12 to 15 in the EU Company

The European Medicines Agency (EMA) on Friday supported the extension of the use of the Pfizer / BioNTech vaccine to adolescents between 12 and 15 years old, making it the first preparation against COVID-19 with scientific support in the European Union for those under 16 years old.

At a press conference, Marco Cavaleri, head of vaccine strategy, confirmed this “pediatric indication” agreed today at an extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP), which concluded that the vaccine is “safe” and effective. in children of this age group.